july 6 2005 scolr pharma inc amex ddd 3625 132 nd avenue se suite 300 bellevue washington 98006 off ice 425 373 0171 ext 1017? fax 0181 www com daniel o wilds president and ceo email danowild aol recent developments initial controled delive ry technology cdt drug targets are in clinical trials including 12hr ibuprofen is us product registration trials? pseudoephedrine has comple te d its registra tion immediate release raloxifene enter ed c linical evaluation q 2 submited 4th major platform patent application methodology involv ing the combination of drugs multiple layers with diferent propertie s a single tablet continuing licensing partnership discussions large pharmaceutical generic companies completed 15 0 milion equity financing february company overview based belevue specialty that leverages formulation expertise proprietary patented delivery technologies to introduce distinctive novel over counter nutritional products enjoys significant diferen tiated intelectual property position consisting thre 3 young broadly applicable patents first unique
